The Novo Nordisk Foundation and University of Copenhagen researchers have backtracked over a project to redefine how the ...

Novo Nordisk on Monday revealed weaker-than-expected data from a second late-stage trial of its obesity drug candidate ...

We've identified the following companies as similar to Novo Nordisk A/S because they operate in a related industry or sector. We also considered size, growth, and various financial metrics to ...

Also, Novo Nordisk offers the possibility of viewing the Annual General Meeting via live webcast on Novo Nordisk's website. Please refer to the enclosed notice for the Annual General Meeting for ...

Drug compounders aren’t ready to give up their ability to produce off-brand versions of Novo Nordisk’s weight-loss drug Wegovy and diabetes treatment Ozempic without a fight. An industry group ...

Novo Nordisk shares rallied on Tuesday as a maker of a weight-loss drug alternative confirmed it won’t be selling it for much longer. Hims & Hers Health Inc.’s stock plunged last week when the ...

Investors are scrambling to adjust, after the telehealth specialist Hims & Hers said it would stop selling an alternative to Novo Nordisk's Wegovy and Ozempic weight-loss drugs. Hims stock stood ...

Dr Avsar Tuna joined Novo Nordisk in 2000. All the news that moves the needle in pharma and biotech Exclusive features, podcasts, interviews, data analyses and commentary from our global network of ...

ClearBridge Large Cap Growth Strategy stated the following regarding Novo Nordisk A/S (NYSE:NVO) in its Q4 2024 investor letter: “Similarly, we used a temporary price dislocation caused by ...

AS Heart Month reminds us of the critical need to protect our cardiovascular and metabolic health, Novo Nordisk Philippines and the Philippine College of Endocrinology, Diabetes and Metabolism (PCEDM) ...

The drugmaker Novo Nordisk can meet current and future demand in the U.S., the Food and Drug Administration said. But patients may still see some supply disruptions as the medications move from ...